Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temporary Inactivation of Strong Muscle Sensation to Improve Rehabilitation Interventions in SCI
NCT05589402Phase 1Completed
- Sponsor
- UT Rio Grande Valley
- Start
- Jun 2019
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1 trial of lidocaine 10% oropharyngeal spray in spinal cord injury (SCI) (2 arms), sponsored by UT Rio Grande Valley. Primary endpoints: Electromyography at 4 weeks and Transcranial Magnetic Stimulation at 4 weeks. Started Jun 2019; status: completed.
02
Drugs
lidocaine 10% oropharyngeal spray
03
Conditions
spinal cord injury (SCI)
Beyond the preview
Go deeper on NCT05589402.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05589402.